Science & Research

Research findings and the scientific background of PIPAC therapy

Our research for better therapies

At the German PIPAC Center, treatment and research go together. Our team has been working on the further development of PIPAC therapy for more than 13 years, so that people with peritoneal cancer can be treated better.

Research as the foundation for progress

Progress in PIPAC therapy rests on years of scientific work. At our centre, clinical experience and new research findings feed directly into the treatment of our patients.

Our research focuses on the further development of the PIPAC procedure, the optimisation of dosages and treatment protocols, studies on efficacy and tolerability, and collaboration with national and international research institutions.

Our research has formed the basis for more than 35 scientific publications in renowned journals. It provides the foundation for the continuous improvement of treatment and for the worldwide adoption of the PIPAC method.

2,500+ PIPAC procedures performed

35+ scientific publications

13+ years of research & development

Publications

Below you will find an overview of the most important scientific publications on PIPAC therapy from recent years in which the German PIPAC Center was involved.

Karam E, Kockelmann F, Romdhane V, Barbey S, Viel R, Sébillot A, Roger S, Michot N, Giger-Pabst U, Ouaissi M. Comparative Analysis of PIPAC Nozzle Designs: Ex Vivo Evaluation of Aerosol Distribution, Penetration, and Tissue Concentration.Ann Surg Oncol. 2026.

Karam E, Kockelmann F, Romdhane V, Barbey S, Viel R, Sébillot A, Roger S, Michot N, Giger-Pabst U, Ouaissi M. ASO Visual Abstract: Comparative Analysis of PIPAC Nozzle Designs: Ex Vivo Evaluation of Aerosol Distribution, Penetration and Tissue Concentration.Ann Surg Oncol. 2026.

Karam E, Kockelmann F, Bucur P, Michot N, Ouaissi A, Barbay S, Ouguerri L, Romdhane V, Roger S, Giger-Pabst U, Ouaissi M. Comparative Evaluation of Nozzle Designs for Enhanced Oxaliplatin Delivery in Pressurized IntraPeritoneal Aerosol Chemotherapy: An In Vivo Study of a Porcine Model.Ann Surg Oncol. 2025.

Tozzi F, Rashidian N, Ceelen W, Callebout E, Hübner M, Sgarbura O, Willaert W; INPACT study group. Standardizing eligibility and patient selection for Pressurized Intraperitoneal Aerosol Chemotherapy: A Delphi consensus statement.Eur J Surg Oncol. 2024.

Göhler D, Oelschlägel K, Ouaissi M, Giger-Pabst U. Performance of different nebulizers in clinical use for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC).PLoS One. 2024.

Kockelmann F, Giger-Pabst U, Ouaissi M, Bucur P, Barbey S, VON Ardenne A, Zieren J. First Clinical Safety and Feasibility Data of Whole-body Hyperthermia Pressurized Intraperitoneal Aerosol Chemotherapy (WBH-PIPAC) for Peritoneal Surface Malignancies.Anticancer Res. 2024.

Ramos Arias G, Sindayigaya R, Ouaissi M, Buggisch JR, Schmeding M, Giger-Pabst U, Zieren J. Safety and Feasibility of High-Pressure/High-Dose Pressurized Intraperitoneal Aerosol Chemotherapy (HP/HD-PIPAC) for Primary and Metastatic Peritoneal Surface Malignancies.Ann Surg Oncol. 2023.

Sindayigaya R, Dogan C, Demtröder CR, Fischer B, Karam E, Buggisch JR, Tempfer CB, Lecomte T, Ouaissi M, Giger-Pabst U. Clinical Outcome for Patients Managed with Low-Dose Cisplatin and Doxorubicin Delivered as Pressurized Intraperitoneal Aerosol Chemotherapy for Unresectable Peritoneal Metastases of Gastric Cancer.Ann Surg Oncol. 2022.

Tabchouri N, Buggisch J, Demtröder CR, Thiery J, Rezniczek G, Tempfer CB, Fischer B, Dogan C, Lecomte T, Ouaissi M, Giger-Pabst U. Pressurized Intraperitoneal Aerosol Chemotherapy for Colorectal Peritoneal Metastases.Ann Surg Oncol. 2021.

Göhler D, Geldner A, Gritzki R, Lohse F, Große S, Sobilo J, Felsmann C, Buggisch JR, Le Pape A, Rudolph A, Stintz M, Giger-Pabst U. Development of a rat capnoperitoneum phantom to study drug aerosol deposition in the context of anticancer research on peritoneal carcinomatosis.Sci Rep. 2021.

Rezniczek GA, Giger-Pabst U, Thaher O, Tempfer CB. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for rare gynecologic indications: peritoneal metastases from breast and endometrial cancer.BMC Cancer. 2020.

Rezniczek GA, Buggisch J, Sobilo J, Launay A, Lerondel S, Le Pape A, Ouaissi M, Göhler D, Senkal M, Giger-Pabst U, Tempfer CB. Establishment of a Mouse Ovarian Cancer and Peritoneal Metastasis Model to Study Intraperitoneal Chemotherapy.Cancers (Basel). 2020.

Giger-Pabst U, Bucur P, Roger S, Falkenstein TA, Tabchouri N, Le Pape A, Lerondel S, Demtröder C, Salamé E, Ouaissi M. Comparison of Tissue and Blood Concentrations of Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy.Ann Surg Oncol. 2019.

Falkenstein TA, Götze TO, Ouaissi M, Tempfer CB, Giger-Pabst U, Demtröder C. First Clinical Data of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as Salvage Therapy for Peritoneal Metastatic Biliary Tract Cancer.Anticancer Res. 2018.

Giger-Pabst U, Demtröder C, Falkenstein TA, Ouaissi M, Götze TO, Rezniczek GA, Tempfer CB. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.BMC Cancer. 2018.

Tempfer CB, Giger-Pabst U, Seebacher V, Petersen M, Dogan A, Rezniczek GA. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis.Gynecol Oncol. 2018.

Tempfer C, Giger-Pabst U, Hilal Z, Dogan A, Rezniczek GA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer.Arch Gynecol Obstet. 2018.

Giger-Pabst U, Tempfer CB. How to Perform Safe and Technically Optimized Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Experience After a Consecutive Series of 1200 Procedures.J Gastrointest Surg. 2018.

Khosrawipour V, Diaz-Carballo D, Acikelli AH, Khosrawipour T, Falkenstein TA, Wu D, Zieren J, Giger-Pabst U. Cytotoxic effect of different treatment parameters in pressurized intraperitoneal aerosol chemotherapy (PIPAC) on the in vitro proliferation of human colonic cancer cells.World J Surg Oncol. 2017.

Bellendorf A, Khosrawipour V, Khosrawipour T, Siebigteroth S, Cohnen J, Diaz-Carballo D, Bockisch A, Zieren J, Giger-Pabst U. Scintigraphic peritoneography reveals a non-uniform 99mTc-Pertechnetat aerosol distribution pattern for Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a swine model.Surg Endosc. 2017.

Khosrawipour T, Khosrawipour V, Giger-Pabst U. Pressurized Intra Peritoneal Aerosol Chemotherapy in patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma.PLoS One. 2017.

Göhler D, Große S, Bellendorf A, Falkenstein TA, Ouaissi M, Zieren J, Stintz M, Giger-Pabst U. Hyperthermic intracavitary nanoaerosol therapy (HINAT) as an improved approach for pressurised intraperitoneal aerosol chemotherapy (PIPAC): Technical description, experimental validation and first proof of concept.Beilstein J Nanotechnol. 2017.

Demtröder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis.Colorectal Dis. 2016.

Khosrawipour V, Giger-Pabst U, Khosrawipour T, Pour YH, Diaz-Carballo D, Förster E, Böse-Ribeiro H, Adamietz IA, Zieren J, Fakhrian K. Effect of Irradiation on Tissue Penetration Depth of Doxorubicin after Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a Novel Ex-Vivo Model.J Cancer. 2016.

Göhler D, Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Falkenstein TA, Zieren J, Stintz M, Giger-Pabst U. Technical description of the microinjection pump (MIP®) and granulometric characterization of the aerosol applied for pressurized intraperitoneal aerosol chemotherapy (PIPAC).Surg Endosc. 2016.

Khosrawipour V, Khosrawipour T, Kern AJ, Osma A, Kabakci B, Diaz-Carballo D, Förster E, Zieren J, Fakhrian K. Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. J Cancer Res Clin Oncol. 2016.

Khosrawipour V, Khosrawipour T, Falkenstein TA, Diaz-Carballo D, Förster E, Osma A, Adamietz IA, Zieren J, Fakhrian K. Evaluating the Effect of Micropump© Position, Internal Pressure and Doxorubicin Dosage on Efficacy of Pressurized Intra-peritoneal Aerosol Chemotherapy (PIPAC) in an Ex Vivo Model.Anticancer Res. 2016.

Oyais A, Solass W, Zieren J, Reymond MA, Giger-Pabst U. Arbeitssicherheitsaspekte der intraperitonealen Druck-Aerosol-Chemotherapie (PIPAC): Bestätigung der Unbedenklichkeit [Occupational Health Aspects of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC): Confirmation of Harmlessness].Zentralbl Chir. 2016.

Tempfer CB, Winnekendonk G, Solass W, Horvat R, Giger-Pabst U, Zieren J, Rezniczek GA, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study.Gynecol Oncol. 2015.

Giger-Pabst U, Solass W, Buerkle B, Reymond MA, Tempfer CB. Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) as an alternative therapy for ovarian cancer in an octogenarian patient.Anticancer Res. 2015.

Odendahl K, Solass W, Demtröder C, Giger-Pabst U, Zieren J, Tempfer C, Reymond MA. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC).Eur J Surg Oncol. 2015.

Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis.J Gastrointest Surg. 2015.

Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Förster E, Zieren J, Giger-Pabst U. Exploring the Spatial Drug Distribution Pattern of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC).Ann Surg Oncol. 2015.

Solass W, Kerb R, Mürdter T, Giger-Pabst U, Strumberg D, Tempfer C, Zieren J, Schwab M, Reymond MA. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2013

Solass W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol. 2013.

Blanco A, Giger-Pabst U, Solass W, Zieren J, Reymond MA. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2013.

PIPAC publications worldwide

All scientific publications on PIPAC therapy, loaded automatically from the medical database PubMed.

Loading publications from PubMed…

Provided by PubMed / National Library of Medicine

Clinical trials

Current and completed clinical trials on PIPAC therapy from the international registry ClinicalTrials.gov.

Loading trials from ClinicalTrials.gov…

Provided by ClinicalTrials.gov / U.S. National Library of Medicine

Interested in working with us?

Are you a scientist, a physician or a medical institution and would like to learn more about PIPAC? Get in touch with us.

Quality and standards

The German PIPAC Center works to the highest medical quality standards. Our procedures, devices and processes are subject to strict quality controls and are certified to international standards.

Our close collaboration with our technology partners REGER Medizintechnik, VON ARDENNE and Technomedics ensures that we always work with state-of-the-art equipment.